Lexicon Pharmaceuticals, Inc. (LXRX): Total Assets
$184.99M
As of 2025-12-31
$250.06M
As of 2026-06-30
-1.6%
3-year compound annual growth
-1.9%
5-year compound annual growth
-11.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $184.99M | -38.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $298.42M | +30.1% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $229.43M | +18.1% | 2025-03-07, Balance as of period end |
| 2022-12-31 | $194.30M | +41.9% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $136.91M | -32.8% | 2023-03-03, Balance as of period end |
| 2020-12-31 | $203.79M | -51.2% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $417.71M | +47.0% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $284.14M | -34.9% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $436.54M | -8.2% | 2019-03-15, Balance as of period end |
| 2016-12-31 | $475.62M | -27.0% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $651.96M | +38.3% | 2017-03-06, Balance as of period end |
| 2014-12-31 | $471.38M | +71.9% | 2016-03-11, Balance as of period end |
| 2013-12-31 | $274.16M | -26.3% | 2015-03-12, Balance as of period end |
| 2012-12-31 | $371.78M | -13.6% | 2014-03-07, Balance as of period end |
| 2011-12-31 | $430.51M | +17.3% | 2013-03-11, Balance as of period end |
| 2010-12-31 | $366.88M | n/a | 2012-03-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $808.06M | +76.5% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $61.78M | -33.1% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $668.19M | -10.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $596.19M | +30.6% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $1.30B | -22.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $280.41M | -7.7% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $160.43M | +58.2% |
Compare LXRX, GOSS, OCUL, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗